Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Vir Biotechnology (VIR) has 8 years of Current Deferred Revenue data on file, last reported at $10.1 million in Q2 2025.

• For the quarter ending Q2 2025, Current Deferred Revenue fell 39.47% year-over-year to $10.1 million; the trailing twelve-month figure through Jun 2025 stood at $10.1 million (down 39.47% YoY), and the FY2024 full-year result was $12.6 million, down 80.5% from the prior year.
• Current Deferred Revenue eased to $10.1 million in Q2 2025, from $11.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $262.9 million in Q1 2021 to a low of $10.1 million in Q2 2025.
• A 5-year average of $48.0 million and a median of $16.2 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 5148.08% in 2021 and tumbled 94.1% in 2022, its largest moves.
• Tracing VIR's Current Deferred Revenue over 5 years: stood at $98.2 million in 2021, then slumped by 84.2% to $15.5 million in 2022, then soared by 317.95% to $64.9 million in 2023, then slumped by 80.5% to $12.6 million in 2024, then dropped by 20.07% to $10.1 million in 2025.
• Business Quant data shows VIR's Current Deferred Revenue at $10.1 million in Q2 2025, $11.9 million in Q1 2025, and $12.6 million in Q4 2024.